Company Overview and News

16
We're doubling down on the errors that caused the financial crisis a decade ago

7h theage.com.au
Everyone has their favourite theory about the financial crisis. It is now ten years since Lehman Brothers failed and most interested parties have decided what they think. It was deregulation, they claim, or bankers' bonuses, low interest rates, US government housing policy or moral hazard. There is very little hard evidence that any of these popular theories actually caused the particular disaster we experienced in 2008.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
We're doubling down on the errors that caused the financial crisis a decade ago

7h smh.com.au
Everyone has their favourite theory about the financial crisis. It is now ten years since Lehman Brothers failed and most interested parties have decided what they think. It was deregulation, they claim, or bankers' bonuses, low interest rates, US government housing policy or moral hazard. There is very little hard evidence that any of these popular theories actually caused the particular disaster we experienced in 2008.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

22
Oracle Corporation (ORCL) CEO Safra Catz and Mark Hurd on Q1 2019 Results - Earnings Call Transcript

2018-09-18 seekingalpha
Thank you, Victoria. Good afternoon, everyone, and welcome to Oracle’s first quarter fiscal year 2019 earnings conference call. A copy of the press release and financial tables, which includes the GAAP to non-GAAP reconciliation and other financial information, can be viewed and downloaded from our Investor Relations website.
SSREY 530017 FMCKI FMCKJ FREGP N21 ORCL FMCCO FMCCP NBL NOBGF FMCCM FMCCN FMCCK FMCCL FMCCI SIL FMCCJ FMCCG FMCKO LMHA FMCCH FMCKP ZBRA FMCKM LMHB FMCKN FMCKK FMCKL FREJN FREJO FREJP FMCC OCLCF NOBGY NUAN FMCCS LM SSREF

16
Hensarling Says Administration Doesn't Favor His GSE Wind Down

2018-09-17 seekingalpha
Hensarling finally produced legislation, which he proceeded to call bad legislation, and then pointed out that the administration doesn't like his plan.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

25
The Zacks Analyst Blog Highlights: Caterpillar, International Paper, MetLife and Broadcom

2018-09-17 zacks
Chicago, IL – September 17, 2018 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events impacting stocks and the financial markets. Stocks recently featured in the blog include Caterpillar Inc. (CAT - Free Report) , International Paper Company (IP - Free Report) , MetLife, Inc. (MET - Free Report) and Broadcom Limited (AVGO - Free Report) .
CAT MET FNMA FMCKI FMCKJ IP AVGO FMCCO FMCCP FMCCM CATR FMCCN INPAP FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL FMCC BRCM FMCCS FMCCT

16
Lumber Liquidators: '...In The Gutter, But Some Of Us Are Looking At The Stars'

2018-09-17 seekingalpha
“We are all in the gutter, but some of us are looking at the stars”. The quote is from the 19th century Irish poet and playwright Oscar Wilde, but it could have been uttered by Wall Street analysts who follow Lumber Liquidators (LL). Optimism certainly reigns among those analysts about a company that has not turned an annual profit since 2014. Average 2019 earnings for the flooring retailer is projected to be $0.
HD FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
Mobile home values might rise as fast as regular homes—here’s why that matters

2018-09-17 marketwatch
Many have long held the assumption that mobile homes don’t increase in value — or, at the very least, they rise in value at a much slower rate than traditional homes.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
NerdWallet: What to do about your home and mortgage if you’re hit by a disaster

2018-09-17 marketwatch
If you’re affected by a hurricane, flood or another natural disaster, what does it mean for your mortgage? Whether you’re hit by Hurricane Florence or another disaster, this is especially important for homeowners. Here are frequently asked questions and answers.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
Best (and Worst) Cities to Get a Mortgage with Poor Credit

2018-09-16 247wallst
The average credit score for homebuyers seeking a 30-year fixed-rate mortgage is 755. That rate applies to what are known as conventional, conforming loans. Those are mortgage loans for 80% of the value of the property for an amount of up to $453,100 nationally, but that could be higher in high-cost areas.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
Then And Now: Mortgage-Backed Securities Post-Financial Crisis

2018-09-16 seekingalpha
A little over 10 years ago, few people had heard of mortgage-backed securities (MBS). Yet that changed when MBS brought the global financial system to its knees. Today, they're still a pivotal part of the system, with the US Federal Reserve (Fed) the largest holder. Franklin Templeton Fixed Income Group's Paul Varunok explains how MBS fit into the Fed's future plans and gives his outlook for the asset class.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO NYTAB FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
'Unchartered waters': Reflections from the heart of Australia's government during the GFC

2018-09-15 abc.net.au
It was well after ten o'clock on the night of Monday September 15th 2008 when Kevin Rudd left a cabinet meeting to take an urgent call.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
10 years of the 2008 financial crisis: A timeline of events

2018-09-15 moneycontrol
The worst financial crisis since the Great Depression hit the US markets and rapidly spread across the globe in 2008. There were warning signs as early as 2004, but a combination of exuberance, ignorance, complacency and greed ensured that the party in the financial markets went on uninterrupted for another three years before the problems became too big to ignore.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
Navigating 'unchartered waters': Reflections from the heart of Australia's government during the GFC

2018-09-15 abc.net.au
It was well after ten o'clock on the night of Monday September 15th 2008 when Kevin Rudd left a cabinet meeting to take an urgent call.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ FMCC FMCCS FMCCT

16
Ten years after the GFC, Lehman zombie is a money machine for lawyers

2018-09-14 theage.com.au
I suppose it's like being mugged by a corpse. Losing to Lehman Brothers in court, I mean.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ LHHMQ FMCC FMCCS FMCCT

16
Ten years after the GFC, Lehman zombie is a money machine for lawyers

2018-09-14 smh.com.au
I suppose it's like being mugged by a corpse. Losing to Lehman Brothers in court, I mean.
FMCCO FMCCP FMCCM FMCCN FMCCI FMCCJ FMCCG FMCKO FMCKP FMCKM FMCKN FNMA FMCKK FMCKL FMCKI FMCKJ LHHMQ FMCC FMCCS FMCCT

Related Articles

RIGL: Rigel Pharmaceuticals Analysis and Research Report

2018-09-18 - Asif

Overview Rigel Pharmaceuticals is a biotechnology company dedicated to discovering, developing and providing novel small molecule drugs that significantly improve the lives of patients with immune and hematologic disorders, cancer and rare diseases. The company's pioneering research focuses on signaling pathways that are critical to disease mechanisms. The company's first FDA-approved product is TAVALISSE™ (fostamatinib disodium hexahydrate), an oral spleen tyrosine kinase (SYK) inhibitor, for the treatment of adult patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment. The company's current clinical programs include Phase 2 studies of fostamatinib in autoimmune hemolytic anemia and IgA nephropathy, and a Phase 1 study for its IRAK program. In addition, Rigel Pharmaceuticals has product candidates in development with partners BerGenBio AS, Daiichi Sankyo, and Aclaris Therapeutics. Since inception, Rigel Pharmaceuticals h...

EKSO: Ekso Bionics Holdings Analysis and Research Report

2018-09-18 - Asif

Overview The company design, develop and sell exoskeleton technology to augment human strength, endurance and mobility. The company's exoskeleton technology serves multiple markets and can be used both by able-bodied users as well as by persons with physical disabilities. Ekso Bionics has sold, rented or leased devices that (a) enable individuals with neurological conditions affecting gait (stroke and spinal cord injury) to rehabilitate and to walk again and (b) allow industrial workers to perform heavy duty work for extended periods. Today, its medical exoskeleton, Ekso GT, is used as a rehabilitation tool to allow physicians and therapists to rehabilitate patients who have suffered a stroke or spinal cord injury. With its unique features designed specifically for hospitals and its proprietary SmartAssist software, Ekso GT allows for the early mobilization of patients, with high step count and high dosage treatments. The intent is to allow the patient’s central nervous syst...

AGRX: Agile Therapeutics Analysis and Research Report

2018-09-18 - Asif

Overview Agile Therapeutics is a forward-thinking women’s healthcare company dedicated to fulfilling the unmet health needs of today’s women. Twirla® and its other current potential product candidates are designed to provide women with contraceptive options that offer greater convenience and facilitate compliance. The company's lead product candidate, Twirla, also known as AG200-15, is a once-weekly prescription contraceptive patch that is at the end of Phase 3 clinical development. Since its inception in 1997, Agile Therapeutics has devoted substantial resources to developing Twirla, building its intellectual property portfolio, business planning, raising capital and providing general and administrative support for these operations. The company incurred research and development expenses of $14.4 million, $20.9 million and $25.6 million during the years ended December 31, 2017, 2016 and 2015, respectively. The company incurred research and development expenses of $2.4 milli...

CUSIP: 313400665